{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methamphetamine
to a specific field?
Status:
Other
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Other
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Status:
US Previously Marketed
Source:
Bantron by Campana
(1953)
Source URL:
First marketed in 1882
Source:
Lobeline Sulphate by E. Merck
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Lobeline is an alkaloid found in "Indian tobacco" (Lobelia inflata), "Devil's tobacco" (Lobelia tupa), "cardinal flower" (Lobelia cardinalis), "great lobelia" (Lobelia siphilitica), and Hippobroma longiflora. Additionally, it is also found in Lobelia Chinensis. In its pure form, it is a white amorphous powder which is freely soluble in water. Lobeline has been sold, in tablet form, for use as a smoking cessation aid, and may have application in the treatment of other drug addictions such as addiction to amphetamines, cocaine, or alcohol. Lobeline has multiple mechanisms of action, acting as a VMAT2 ligand, which stimulates dopamine release to a moderate extent when administered alone, but reduces the dopamine release caused by methamphetamine. It also inhibits the reuptake of dopamine and serotonin and acts as a mixed agonist-antagonist at nicotinic acetylcholine receptors to which it binds at the subunit interfaces of the extracellular domain. It is also an antagonist at μ-opioid receptors. It seems to be a P-glycoprotein inhibitor, according to at least one study. It has been hypothesized that P-glycoprotein inhibition reduces chemotherapeutic resistance in cancer, presumably affecting any substrates of P-gp.
Status:
Possibly Marketed Outside US
Source:
21 CFR 355
(2010)
Source URL:
First approved in 2010
Source:
21 CFR 355
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
NCT01227616: Phase 4 Human clinical trial Completed Anemia, Iron-Deficiency/etiology
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Glucaric acid is a non-toxic, naturally occurring compound, which is found in small amounts in plants and mammals, including humans. Salts of glucaric acid have potent antiproliferative properties in vivo. The risk of cancer development can be reduced by ingesting food rich in glucaric acid or self-medication with its salts. Glucaric acid inhibits bacterial beta-glucuronidase, thus increasing the excretion of conjugated xenobiotic compounds and decreasing activity of harmful substances. Inhibition of beta-glucuronidase ultimately results in potentially decreasing the risk of carcinogenesis. Calcium salt of the acid demonstrated anti-cancer activity in patients with breast cancer (phase I clinical trial) and in preclinical models of liver, lung, colon and skin cancers. Calcium-D-glucarate is being marketed as a dietary supplement.
Status:
Investigational
Source:
INN:devextinetug [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03333824: Phase 1 Interventional Completed Solid Tumours
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03534063: Not Applicable Interventional Completed Pain, Postoperative
(2018)
Source URL:
Class:
PROTEIN
